Literature DB >> 11964707

Reactive metabolites and their role in drug reactions.

D J Naisbitt1, D P Williams, M Pirmohamed, N R Kitteringham, B K Park.   

Abstract

Adverse drug reactions are a major clinical problem and often preclude drug administration. Drug hypersensitivity (or allergy) represents one of the most severe and unpredictable reactions associated with drug therapy. Our current understanding of drug hypersensitivity is based on the hapten hypothesis of immune recognition of drugs by T cells. The onset of hypersensitivity involves drug bioactivation, covalent binding, followed by uptake, antigen processing and T cell proliferation. There is convincing evidence that drugs associated with a high incidence of hypersensitivity are converted to protein reactive intermediates by the normal processes of drug metabolism and stimulate a cellular immune response in sensitive individuals. Until recently, however, there has been little evidence to relate the formation of a reactive metabolite to the initiation of a cellular immune response. The purpose of this review is to detail recent advances in our understanding of the complex mechanisms of drug hypersensitivity, and using severe skin reactions as an example, assess recent evidence that supports the hapten hypothesis of drug hypersensitivity.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11964707     DOI: 10.1097/01.all.0000011033.64625.5a

Source DB:  PubMed          Journal:  Curr Opin Allergy Clin Immunol        ISSN: 1473-6322


  13 in total

Review 1.  In vitro testing for diagnosis of idiosyncratic adverse drug reactions: Implications for pathophysiology.

Authors:  Abdelbaset A Elzagallaai; Michael J Rieder
Journal:  Br J Clin Pharmacol       Date:  2015-06-01       Impact factor: 4.335

Review 2.  Immunotoxicology: role in the safety assessment of drugs.

Authors:  Jacques Descotes
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

Review 3.  GSTM1 and GSTT1 genetic polymorphisms and risk of anti-tuberculosis drug-induced hepatotoxicity: an updated meta-analysis.

Authors:  C Li; J Long; X Hu; Y Zhou
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-02-02       Impact factor: 3.267

4.  Influence of chemical structure on hypersensitivity reactions induced by antiepileptic drugs: the role of the aromatic ring.

Authors:  Kim B Handoko; Eugène P van Puijenbroek; Annemarie H Bijl; Walter A J J Hermens; Jeannette E F Zwart-van Rijkom; Yechiel A Hekster; Toine C G Egberts
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

Review 5.  Immunopharmacology of hypersensitivity reactions to drugs.

Authors:  Dean J Naisbitt; Munir Pirmohamed; B Kevin Park
Journal:  Curr Allergy Asthma Rep       Date:  2003-01       Impact factor: 4.919

6.  In vitro release of interferon-gamma from peripheral blood lymphocytes in cutaneous adverse drug reactions.

Authors:  Ilan Goldberg; Meital Hanson; Gabriel Chodick; Idit Shirazi; Sarah Brenner
Journal:  Clin Dev Immunol       Date:  2012-06-06

7.  LC-ESI-MS/MS reveals the formation of reactive intermediates in brigatinib metabolism: elucidation of bioactivation pathways.

Authors:  Adnan A Kadi; Mohamed W Attwa; Hany W Darwish
Journal:  RSC Adv       Date:  2018-01-03       Impact factor: 3.361

8.  Metabolic Forest: Predicting the Diverse Structures of Drug Metabolites.

Authors:  Tyler B Hughes; Na Le Dang; Ayush Kumar; Noah R Flynn; S Joshua Swamidass
Journal:  J Chem Inf Model       Date:  2020-09-16       Impact factor: 4.956

9.  Cytochrome P450 2E1 gene polymorphisms/haplotypes and anti-tuberculosis drug-induced hepatitis in a Chinese cohort.

Authors:  Shaowen Tang; Xiaozhen Lv; Yuan Zhang; Shanshan Wu; Zhirong Yang; Yinyin Xia; Dehua Tu; Peiyuan Deng; Yu Ma; Dafang Chen; Siyan Zhan
Journal:  PLoS One       Date:  2013-02-27       Impact factor: 3.240

10.  Pharmacogenetic study of drug-metabolising enzyme polymorphisms on the risk of anti-tuberculosis drug-induced liver injury: a meta-analysis.

Authors:  Yu Cai; JiaYong Yi; ChaoHui Zhou; XiZhong Shen
Journal:  PLoS One       Date:  2012-10-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.